Skip to Main Content

The (POGO) Blog

June 8, 2017

By Laura Peterson

More Trump Appointees Get Waived Past Ethics Pledge



White House Ethics Waiver The Office of Government Ethics posted waivers to the ethics pledge for 10 Trump appointees after demanding them from federal agencies.

Continue Reading More Trump Appointees Get Waived Past Ethics Pledge

Topics: Government Accountability, Open Government

June 1, 2017

By Scott H. Amey, J.D.

White House Releases Ethics Waivers After Battle with OGE



White House Ethics Waiver The White House reversed its decision to fight the Office of Government Ethics over the release of government ethics records the day after POGO requested that it should proactively release copies of ethics waivers on public websites.

Continue Reading White House Releases Ethics Waivers After Battle with OGE

Topics: Government Accountability

April 6, 2017

By Nick Schwellenbach

Advisors to the President Should Be Subject to Ethics Laws



Stephen Feinberg In a letter to White House Counsel, POGO urged the White House to make Stephen Feinberg and Carl Icahn subject to federal ethics laws given their vast conflicts of interest.

Continue Reading Advisors to the President Should Be Subject to Ethics Laws

Topics: Government Accountability

March 28, 2017

By Ari Goldberg

POGO's 2017 Baker’s Dozen Wishlist for Congress



Aerial U.S. Capitol Building The Project On Government Oversight (POGO) has unveiled its biennial list of 13 policy areas ripe for Congressional action. It includes recommendations for legislative fixes to make the federal government more transparent, accountable, and ethical.

Continue Reading POGO's 2017 Baker’s Dozen Wishlist for Congress

Topics: Government Accountability, Open Government, Whistleblower Protections, Energy and Natural Resources, National Security, Public Health and Science, Contract Oversight

March 3, 2017

By David S. Hilzenrath

Trump’s Dangerous Prescription for the FDA



President Trump addressing a joint session of Congress, with VP Mike Pence and Rep. Paul Ryan seated behind him, clapping. President Donald Trump called the FDA drug approval process slow and burdensome, but the evidence he cited could point to the opposite conclusion. Slashing regulatory restraints as he proposed could pose medical and financial hazards.

Continue Reading Trump’s Dangerous Prescription for the FDA

Topics: Government Accountability, Open Government, Public Health and Science

Items 1 - 5 of 64  12345678910Next

Browse POGOBlog by Topic

POGO on Facebook